A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/198 (2006.01) A61K 31/17 (2006.01) A61K 31/175 (2006.01) A61K 31/4745 (2006.01) A61K 47/00 (2006.01)
Patent
CA 2456983
The present invention provides a combination therapy using eflornithine (DFMO) and PCV (matulane, lomustine and vincristine) in the treatment of anaplastic gliomas. In contrast to the results seen with glioblastoma multiforme, anaplastic gliomas responded better to the combination of DFMO and PCV than to either the PCV combination or DFMO alone, extending patient survival by approximately two years.
L'invention concerne une thérapie de combinaison utilisant de l'éflornithine (DFMO) et du PCV (matulane, lomustine et vincristine) dans le traitement de gliomes anaplasiques. A la différence des résultats observés avec le glioblastome multiforme, les gliomes anaplasiques répondent mieux à la combinaison de DFMO et PCV que soit à la combinaison de PCV soit au DFMO tout seul, prolongeant la vie des patients d'environ deux ans.
Levin Victor A.
Board Of Regents The University Of Texas
Goudreau Gage Dubuc
LandOfFree
Adjuvant chemotherapy for anaplastic gliomas does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Adjuvant chemotherapy for anaplastic gliomas, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Adjuvant chemotherapy for anaplastic gliomas will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1811870